• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of child neurology >Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation
【24h】

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

机译：男性杜氏肌营养不良症的皮质类固醇治疗：治疗持续时间和失去运动的时间

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This population-based study examines the association between corticosteroid treatment and time to loss of ambulation, stratifying by treatment duration (short: 0.25-3 years, long: >3 years), among 477 Duchenne muscular dystrophy cases identified by the Muscular Dystrophy Surveillance Tracking and Research Network (MDSTARnet). Those cases who received short-term corticosteroid treatment had a time to loss of ambulation that was 0.8 years shorter (t test) and an annual risk of losing ambulation 77% higher than the untreated (Cox regression). Conversely, cases who received long-term corticosteroid treatment had a time to loss of ambulation that was 2 years longer and an annual risk of losing ambulation 82% lower than the untreated, up to age 11 years; after which the risks were not statistically different. The relationship of corticosteroids and time to loss of ambulation is more complex than depicted by previous studies limited to treatment responders or subjects who lost ambulation during study follow-up.
机译：这项基于人群的研究检查了477例由肌肉营养不良监测追踪发现的杜兴氏肌营养不良病例中，皮质类固醇治疗与失去运动的时间之间的关联，并按治疗持续时间（短：0.25-3年，长：> 3年）进行分层。和研究网络（MDSTARnet）。那些接受短期皮质类固醇激素治疗的患者，其下肢活动时间缩短了0.8年（t检验），并且每年发生下肢活动的风险比未接受治疗的患者高77％（Cox回归）。相反，长期接受皮质类固醇激素治疗的患者，到11岁时，失去活动能力的时间要比未接受治疗的时间长2年，每年失去活动能力的风险比未经治疗的患者低82％。之后，风险在统计学上没有差异。皮质类固醇和时间与运动减少的关系比以前的研究更为复杂，以前的研究仅限于治疗反应者或研究随访期间失去运动的受试者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号